Safety and Efficacy Evaluation of 4SCAR19 Chimeric Antigen Receptor-Modified T Cells Targeting B Cell Acute Lymphoblastic Leukemia - Three-Year Follow-up of a Multicenter Phase I/II Study
机构:[1]Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL[2]Shenzhen Genoimmune Medical Institute (GIMI), Shenzhen, China[3]BMT Center, Fu Dan University Shanghai Dao-Pei Hospital, Shanghai, China[4]Department of Biomedical Informatics, Biodesign Institute, Arizona State University, Tempe, AZ[5]Hebei Yanda Lu Daopei Hospital, Beijing, China[6]Department of Hematology, Beijing Aerospace General Hospital, Beijing, China[7]Department of Pediatric Hematology, Peking University, People's Hospital, Beijing, China[8]Department of Pediatric Hematology, Beijing Children's Hospital, Capital Medical University, Beijing, China首都医科大学附属北京儿童医院[9]Department of Hematology, Air Force General Hospital, PLA, Beijing, China[10]Department of Hematology, First People's Hospital of Yunnan Province, Kunming, China内科片血液内科云南省第一人民医院[11]Department of Hematology, Ming-Ji Hospital, Nanjing, China
第一作者机构:[1]Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL[2]Shenzhen Genoimmune Medical Institute (GIMI), Shenzhen, China
推荐引用方式(GB/T 7714):
Chang Lung-Ji,Dong Lujia,Liu Yu-Chen,et al.Safety and Efficacy Evaluation of 4SCAR19 Chimeric Antigen Receptor-Modified T Cells Targeting B Cell Acute Lymphoblastic Leukemia - Three-Year Follow-up of a Multicenter Phase I/II Study[J].BLOOD.2016,128(22):doi:10.1182/blood.V128.22.587.587.
APA:
Chang, Lung-Ji,Dong, Lujia,Liu, Yu-Chen,Tsao, Shih-Ting,Li, Ya-Chen...&Li, Dong.(2016).Safety and Efficacy Evaluation of 4SCAR19 Chimeric Antigen Receptor-Modified T Cells Targeting B Cell Acute Lymphoblastic Leukemia - Three-Year Follow-up of a Multicenter Phase I/II Study.BLOOD,128,(22)
MLA:
Chang, Lung-Ji,et al."Safety and Efficacy Evaluation of 4SCAR19 Chimeric Antigen Receptor-Modified T Cells Targeting B Cell Acute Lymphoblastic Leukemia - Three-Year Follow-up of a Multicenter Phase I/II Study".BLOOD 128..22(2016)